NASDAQ:ZYNEZynerba Pharmaceuticals Stock Price, Forecast & News

$5.26

-0.13 (-2.41 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$5.08

Now: $5.26▼

$5.58

50-Day Range

$3.70

MA: $4.38▼

$6.48

52-Week Range

$2.55

Now: $5.26▼

$15.70

Volume1.20 million shs

Average Volume1.35 million shs

Market Capitalization$131.24 million

P/E RatioN/A

Dividend YieldN/A

Beta3.04

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Zynerba Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.83, Zynerba Pharmaceuticals has a potential upside of 239.0% from its current price of $5.26.
Amount of Analyst Coverage
Zynerba Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Zynerba Pharmaceuticals has received 622 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zynerba Pharmaceuticals has received 552 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zynerba Pharmaceuticals has received 52.98% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote “Outperform” if you believe ZYNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zynerba Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Zynerba Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zynerba Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 10.79% of the stock of Zynerba Pharmaceuticals is held by insiders.
Percentage Held by Institutions
36.97% of the stock of Zynerba Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($1.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zynerba Pharmaceuticals is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zynerba Pharmaceuticals is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zynerba Pharmaceuticals has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZYNE

Previous Symbol

CUSIPN/A

CIK1621443

Webwww.zynerba.com

Phone484-581-7505

Debt

Debt-to-Equity RatioN/A

Current Ratio7.31

Quick Ratio7.31

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$90,000.00

Price / Sales1,458.19

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.65 per share

Price / Book1.98

Profitability

EPS (Most Recent Fiscal Year)($1.50)

Net Income$-32,940,000.00

Net MarginsN/A

Return on Equity-46.27%

Return on Assets-40.82%

Miscellaneous

Employees25

Outstanding Shares24,950,000

Market Cap$131.24 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

How has Zynerba Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZYNE stock has increased by 35.2% and is now trading at $5.26. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zynerba Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zynerba Pharmaceuticals.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Zynerba Pharmaceuticals.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.03. View Zynerba Pharmaceuticals' earnings history.

What price target have analysts set for ZYNE?

7 brokers have issued 12-month price targets for Zynerba Pharmaceuticals' stock. Their forecasts range from $11.00 to $26.00. On average, they anticipate Zynerba Pharmaceuticals' stock price to reach $17.83 in the next year. This suggests a possible upside of 239.0% from the stock's current price. View analysts' price targets for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (5/30/2020)
2. LADENBURG THALM/SH SH analysts commented, "We understand the market’s reaction when focusing on a few items: 1) There was a case of status epilepticus (SE); 2) 96% of patients reported an adverse event (AE); 3) 10/48 (21%) reported a serious adverse event (SAE); 4) Zygel doesn’t work fast enough; 5) 7 of 48 (15%) dropped out for efficacy; and 6) There were only 11 Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) patients. However, we find some perspective on these figures are important to consider: 1. SE has not been found in any previous Zygel trial, including the Phase 2s in adult refractory epilepsy (n=188), osteoarthritis of the knee (n=300) and Fragile X syndrome (FXS; n=16). As we have described in our notes on Buy), SE typically occurs in patients highly compromised by underlying health conditions and/or trauma." (9/18/2019)

Has Zynerba Pharmaceuticals been receiving favorable news coverage?

Media coverage about ZYNE stock has been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zynerba Pharmaceuticals earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutZynerba Pharmaceuticals.

Who are some of Zynerba Pharmaceuticals' key competitors?

Some companies that are related to Zynerba Pharmaceuticals include AC Immune (ACIU), AnaptysBio (ANAB), Atreca (BCEL), Viking Therapeutics (VKTX), NewLink Genetics (NLNK), VBI Vaccines (VBIV), Urogen Pharma (URGN), Emisphere Technologies (EMIS), Xenon Pharmaceuticals (XENE), BioDelivery Sciences International (BDSI), Beyondspring (BYSI), Neoleukin Therapeutics (NLTX), Fulcrum Therapeutics (FULC), DURECT (DRRX) and BioSpecifics Technologies (BSTC). View all competitors.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Insys Therapeutics (INSY), Advanced Micro Devices (AMD) and Innovative Industrial Properties (IIPR).

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people:

Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)
Ms. Terri B. Sebree, Pres (Age 61)
Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)
Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)
Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.40%), ETF Managers Group LLC (5.12%), State Street Corp (1.80%), AdvisorShares Investments LLC (1.50%), Prentice Capital Management LP (1.37%) and Geode Capital Management LLC (1.27%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler and Terri B Sebree. View institutional ownership trends for Zynerba Pharmaceuticals.

Which major investors are selling Zynerba Pharmaceuticals stock?

ZYNE stock was sold by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Morgan Stanley, Deutsche Bank AG, JPMorgan Chase & Co., UBS Group AG, BlackRock Inc., Bank of New York Mellon Corp, and HighTower Advisors LLC. View insider buying and selling activity for Zynerba Pharmaceuticals.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was bought by a variety of institutional investors in the last quarter, including Prentice Capital Management LP, Sphera Funds Management LTD., AdvisorShares Investments LLC, Advisor Group Holdings Inc., State Street Corp, Geode Capital Management LLC, Parametric Portfolio Associates LLC, and Alliancebernstein L.P.. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, and Terri B Sebree. View insider buying and selling activity for Zynerba Pharmaceuticals.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $5.26.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $131.24 million and generates $90,000.00 in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is www.zynerba.com.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff